MedDay Pharmaceuticals
http://www.medday-pharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From MedDay Pharmaceuticals
BeiGene Among Chinese Firms Eyeing Less Crowded SCLC Sector In US Trials
BeiGene, Junshi, Henlius are studying their PD-1, TIGIT and BTLA-targeting assets in US trials for the relatively less crowded indication of small cell lung cancer.
FDA Postmarket Guidance Hammers Home Positions On Foreign Trials, Real-World Evidence
US agency emphasizes and formalizes long-standing viewpoints on hot topics including accelerated approval in a new guidance on postmarket study diversity.
Chinese PD-1s Eye US Approvals Despite Lack Of Action Dates
Although Novartis/BeiGene’s tislelizumab and Coherus /Junshi’s toripalimab have not received a new Prescription Drug User Fee Act (PDUFA) decision date for their biologics license applications in the US, the companies remain hopeful that potential approvals will be granted in the third quarter at the earliest.
Revolution Picks Up Remains Of EQRx In All-Stock Deal
Revolution Medicines is looking to pump the $1bn it will get from the acquisition into its RAS inhibitor pipeline, with trials planned to start in 2024.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- MedDay Pharmaceuticals SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice